These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 24980176)

  • 41. Repeated dosing with oral racemic ketamine as a successful rescue intervention for coping with life events in recurrent major depressive disorder.
    Menon V; Kale A; Balasubramanian I; Andrade C
    Asian J Psychiatr; 2024 Apr; 94():103973. PubMed ID: 38402733
    [No Abstract]   [Full Text] [Related]  

  • 42. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.
    Lally N; Nugent AC; Luckenbaugh DA; Niciu MJ; Roiser JP; Zarate CA
    J Psychopharmacol; 2015 May; 29(5):596-607. PubMed ID: 25691504
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.
    Medeiros da Frota Ribeiro C; Riva-Posse P
    Curr Psychiatry Rep; 2017 Nov; 19(12):107. PubMed ID: 29138992
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
    Miller OH; Moran JT; Hall BJ
    Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comments to Drs. Bahji, Vazquez, and Zarate.
    Drevets WC; Popova V; Daly EJ; Borentain S; Lane R; Cepeda MS; Mathews M; Manji HK; Canuso CM
    J Affect Disord; 2021 Mar; 283():262-264. PubMed ID: 33571795
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Considerations for use of ketamine to treat depression in Australia and New Zealand.
    Bayes A; Dong V; Loo C
    Aust N Z J Psychiatry; 2019 Nov; 53(11):1117-1120. PubMed ID: 31364369
    [No Abstract]   [Full Text] [Related]  

  • 47. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
    Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The immunomodulatory effect of ketamine in depression.
    Szałach ŁP; Lisowska KA; Słupski J; Włodarczyk A; Górska N; Szarmach J; Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wiglusz MS; Wilkowska A; Cubała WJ
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):252-257. PubMed ID: 31488736
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder.
    Murrough JW; Collins KA; Fields J; DeWilde KE; Phillips ML; Mathew SJ; Wong E; Tang CY; Charney DS; Iosifescu DV
    Transl Psychiatry; 2015 Feb; 5(2):e509. PubMed ID: 25689570
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ketamine for chronic depression: two cautionary tales.
    Talbot J; Phillips JL; Blier P
    J Psychiatry Neurosci; 2019 Nov; 44(6):384-385. PubMed ID: 31573153
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical and biological predictors of ketamine response in treatment-resistant major depression: Review].
    Romeo B; Choucha W; Fossati P; Rotge JY
    Encephale; 2017 Aug; 43(4):354-362. PubMed ID: 27623117
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comment on Fond and colleagues' systematic review and meta-analysis of ketamine in the treatment of depressive disorders (Psychopharmacology 2014; Jul 20 [Epub ahead of print]).
    McGirr A; Berlim MT
    Psychopharmacology (Berl); 2014 Oct; 231(19):3907-8. PubMed ID: 25176174
    [No Abstract]   [Full Text] [Related]  

  • 53. Ketamine helps a third of patients with treatment resistant depression, finds small UK study.
    Torjesen I
    BMJ; 2014 Apr; 348():g2576. PubMed ID: 24699320
    [No Abstract]   [Full Text] [Related]  

  • 54. Intravenous ketamine for rapid treatment of major depressive disorder in the general medical hospital.
    Gee SH; Wratten C; Cairns R; Santhouse A; Taylor D
    BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34645623
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Brain entropy and neurotrophic molecular markers accompanying clinical improvement after ketamine: Preliminary evidence in adolescents with treatment-resistant depression.
    Roy AV; Thai M; Klimes-Dougan B; Westlund Schreiner M; Mueller BA; Albott CS; Lim KO; Fiecas M; Tye SJ; Cullen KR
    J Psychopharmacol; 2021 Feb; 35(2):168-177. PubMed ID: 32643995
    [TBL] [Abstract][Full Text] [Related]  

  • 56. All Suicidal Ideation Is Not Created Equal: Two Cases of Suicide Attempts During Maintenance Ketamine Treatment.
    Cusin C; Sakurai H; Bentley K; Pedrelli P; Foster S; Fava M; Mischoulon D
    Am J Psychiatry; 2020 Feb; 177(2):173-174. PubMed ID: 32008389
    [No Abstract]   [Full Text] [Related]  

  • 57. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression.
    De Gioannis A; De Leo D
    Aust N Z J Psychiatry; 2014 Jul; 48(7):686. PubMed ID: 24452289
    [No Abstract]   [Full Text] [Related]  

  • 58. Frontiers in Therapy of Treatment-Resistant-Depression: A Future Role of Ketamine?
    Kwak S; Tiller D; Tucker P
    J Okla State Med Assoc; 2015 Mar; 108(3):88-9. PubMed ID: 26242015
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sustained antidepressant response to ketamine.
    Atigari OV; Healy D
    BMJ Case Rep; 2013 Aug; 2013():. PubMed ID: 23960151
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral S-ketamine effective after deep brain stimulation in severe treatment-resistant depression and extensive comorbidities.
    Veraart JKE; Kamphuis J; Schlegel M; Schoevers RA
    BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33495180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.